Adnews

Please login to continue

Username:

Password:

Adnews offers non-subscribers free access to one story per month.

Subscribe for unrestricted access to our content.

Forgot your login or password? Click here.

GLAXO FINDS NEW USE FOR ASTHMA DRUG

Glaxo Wellcome Inc. of Mississauga, Ont. has re-launched a drug for the treatment of chronic obstructive pulmonary disease. Called Serevent, the drug is inhaled twice a day and settles in the bronchi, causing the muscles lining the airways to relax. Serevent will be promoted in medical journal ads created by the Healthwise Creative Resources Group of Toronto. PR will be handled by Hill & Knowlton of Toronto. Serevent has been used for the treatment of asthma since 1994. The most frequent cause of COPD is smoking, with long-term smoking being the cause in up to 90% of cases. It generally affects smokers or ex-smokers over the age 40 or 50.

« Back Next »

Related stories Comments